Galapagos NV Equity-NMS: GLPG

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$43.4

52W high :

$72.11

1Y :

-21.83%

5Y :

-58.66%

Shares O/S :

65.84 M

Market cap :

2.79 B

What is the share price of Galapagos NV today?

Galapagos NV (GLPG) share price as of October 11, 2022, is $42.1. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Galapagos NV?

Yes, Indian Investors can invest in the Galapagos NV (GLPG) Share by opening an international trading account with Angel One.

How can I purchase Galapagos NV shares in India?

Purchasing Galapagos NV (GLPG) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Galapagos NV (GLPG) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Galapagos NV?

Yes, you can purchase fractional shares of Galapagos NV (GLPG) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Galapagos NV?

The market capitalization of Galapagos NV on February 5, 2023, is $2.77 B.

In which sector Galapagos NV belongs?

Galapagos NV operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Galapagos NV stocks?

In order to invest in Galapagos NV (GLPG) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve quality of life of patients across the globe. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.